{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:52:56Z","timestamp":1782319976354,"version":"3.54.5"},"reference-count":35,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008464","name":"EMDO Stiftung","doi-asserted-by":"publisher","award":["1053"],"award-info":[{"award-number":["1053"]}],"id":[{"id":"10.13039\/501100008464","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","award":["FK-20-059"],"award-info":[{"award-number":["FK-20-059"]}],"id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002329","name":"Bundesamt f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["19.002540"],"award-info":[{"award-number":["19.002540"]}],"id":[{"id":"10.13039\/501100002329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,4,4]]},"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate effectiveness of tickborne encephalitis (TBE) vaccination by time interval (&lt;5, 5\u201310 and 10+years) postvaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A retrospective, matched case\u2013control study<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Cases\u2014all adult (age 18\u201379) TBE cases in Switzerland reported via the national mandatory disease reporting surveillance system from 2006 to 2020 (final n=1868). Controls\u2014community controls from a database of randomly selected adults (age 18\u201379) participating in a 2018 cross-sectional study of TBE vaccination in Switzerland (final n=4625).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary outcome measures<\/jats:title>\n                    <jats:p>For cases and controls, the number of TBE vaccine doses received and the time since last vaccination were determined. Individuals were classified as being \u2018unvaccinated\u2019 (0 doses), \u2018incomplete\u2019 (1\u20132 doses) or \u2018complete\u2019 (3+ doses). Individuals with \u2018complete\u2019 vaccination were further classified by time since the last dose was received (&lt;5 years, 5\u201310 years or 10+ years). A conditional logistic regression model was used to calculate vaccine effectiveness (VE: 100 \u00d7 [1\u2212OR]) for each vaccination status category.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>VE for incomplete vaccination was 76.8% (95% CI 69.0% to 82.6%). For complete vaccination, overall VE was 95.0% (95% CI 93.5% to 96.1%). When the most recent dose was received &lt;5 years prior VE was 91.6% (95% CI 88.4% to 94.0%), 95.2% (95% CI 92.4% to 97.0%) when the most recent dose was received 5\u201310 years prior, and 98.5% (95% CI 96.8% to 99.2%) when the most recent dose was received 10+ years prior.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>That VE does not decrease among completely vaccinated individuals over 10+ years since last vaccination supports the longevity of the protective response following complete TBE vaccination. Our findings support the effectiveness of 10-year TBE booster intervals currently used in Switzerland.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-061228","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T08:06:23Z","timestamp":1652774783000},"page":"e061228","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Retrospective, matched case\u2013control analysis of tickborne encephalitis vaccine effectiveness by booster interval, Switzerland 2006\u20132020"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7979-076X","authenticated-orcid":false,"given":"Kyra D","family":"Zens","sequence":"first","affiliation":[{"name":"Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland"},{"name":"Institute for Experimental Immunology, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4704-6570","authenticated-orcid":false,"given":"Sarah R","family":"Haile","sequence":"additional","affiliation":[{"name":"Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-4399","authenticated-orcid":false,"given":"Axel J","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Communicable Diseases Division, Swiss Federal Office of Public Health, Bern, Switzerland"},{"name":"Department of Public Health, Environments and Society, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehardt S","family":"Altpeter","sequence":"additional","affiliation":[{"name":"Communicable Diseases Division, Swiss Federal Office of Public Health, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan S","family":"Fehr","sequence":"additional","affiliation":[{"name":"Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7016-9501","authenticated-orcid":false,"given":"Phung","family":"Lang","sequence":"additional","affiliation":[{"name":"Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"2025121223231447000_12.4.e061228.1","unstructured":"Swiss Federal Office of Public Health. Zahlen zu Infektionskrankheiten - Zeckenenzephalitis FSME [Numbers for Infectious Illnesses - Tick-borne Encephalitis - TBE]., 2021. Available: https:\/\/www.bag.admin.ch\/bag\/de\/home\/zahlen-und-statistiken\/zahlen-zu-"},{"key":"2025121223231447000_12.4.e061228.2","doi-asserted-by":"crossref","first-page":"8769","DOI":"10.1016\/j.vaccine.2011.07.024","article-title":"Vaccines against tick-borne encephalitis: who position paper-recommendations","volume":"29","year":"2011","journal-title":"Vaccine"},{"key":"2025121223231447000_12.4.e061228.3","unstructured":"SEN . Encepur N Fachinfo [Technical Information]: Compendium.ch, 2020. Available: https:\/\/compendium.ch\/product\/105785-encepur-n-inj-susp\/mpro"},{"key":"2025121223231447000_12.4.e061228.4","unstructured":"Swissmedic. FSME-Immun\u00ae CC Fachinfo [Technical Information]: Compendium.ch., 2020. Available: https:\/\/compendium.ch\/product\/1364944-fsme-immun-cc-inj-susp-sep-nadel\/mpro"},{"key":"2025121223231447000_12.4.e061228.5","unstructured":"Swiss Federal Offic of Public Health. Empfehlungen zur Impfung gegen Zeckenenzephalitis [Recommendation for Vaccination against Tick-borne Encephalitis]. 2006. Available: https:\/\/www.bag.admin.ch\/dam\/bag\/de\/dokumente\/nat-gesundheitspolitik\/klimawandel\/hitzewelle\/hintergrundinfos\/info-zecken\/impfempfehlungen.pdf.download.pdf\/impfempfehlungen.pdf"},{"key":"2025121223231447000_12.4.e061228.6","unstructured":"Swiss Federal Offic of Public Health. Schweizerischer Impfplan [Swiss Immunization Schedule]., 2020.https:\/\/www.bag.admin.ch\/bag\/de\/home\/gesund-leben\/gesundheitsfoerderung-und-praevention\/impfungen-prophylaxe\/schweizerischer-impfplan.html https:\/\/www.bag.admin.ch\/bag\/de\/home\/gesund-leben\/gesundheitsfoerderung-und-praevention\/impfungen-prophylaxe\/schweizerischer-impfplan.html"},{"key":"2025121223231447000_12.4.e061228.7","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.vaccine.2012.12.075","article-title":"Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination","volume":"31","author":"Paulke-Korinek","year":"2013","journal-title":"Vaccine"},{"key":"2025121223231447000_12.4.e061228.8","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1016\/j.vaccine.2014.06.028","article-title":"Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety","volume":"32","author":"Beran","year":"2014","journal-title":"Vaccine"},{"key":"2025121223231447000_12.4.e061228.9","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1016\/j.vaccine.2017.03.059","article-title":"Seropersistence of TBE virus antibodies 10 years after first booster vaccination and response to a second booster vaccination with FSME-IMMUN 0.5mL in adults","volume":"35","author":"Konior","year":"2017","journal-title":"Vaccine"},{"key":"2025121223231447000_12.4.e061228.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.08.024"},{"key":"2025121223231447000_12.4.e061228.11","doi-asserted-by":"publisher","DOI":"10.3201\/eid1901.120458"},{"key":"2025121223231447000_12.4.e061228.12","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1016\/j.vaccine.2020.10.022","article-title":"Analysis of tick-borne encephalitis vaccination coverage and compliance in adults in Switzerland, 2018","volume":"38","author":"Baroutsou","year":"2020","journal-title":"Vaccine"},{"key":"2025121223231447000_12.4.e061228.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247216","article-title":"A cross-sectional study evaluating tick-borne encephalitis vaccine uptake and timeliness among adults in Switzerland","volume":"16","author":"Zens","year":"2021","journal-title":"PLoS One"},{"key":"2025121223231447000_12.4.e061228.14","unstructured":"Dobler PDG , Erber W , Br\u00f6ker M . The TBE book. 2nd Edition. Global Health Press Pte Limited;, 2019."},{"key":"2025121223231447000_12.4.e061228.15","unstructured":"Swiss Federal Office of Public Health . Infektionskrankheiten melden - Zeckenenzephalitis FSME [Infectious Disease Reporting - Tick-borne Encephalitis - TBE]., 2021. Available: https:\/\/www.bag.admin.ch\/bag\/de\/home\/krankheiten\/infektionskrankheiten-bekaempfen\/meldesysteme-infektionskrankheiten\/meldepflichtige-ik\/meldeformulare.html#-1611150545."},{"key":"2025121223231447000_12.4.e061228.16","doi-asserted-by":"publisher","DOI":"10.18637\/JSS.V042.I08"},{"key":"2025121223231447000_12.4.e061228.17","doi-asserted-by":"crossref","unstructured":"Hansson K , Rosdahl A , Insulander M . Tick-Borne encephalitis (TBE) vaccine failures: a ten-year retrospective study supporting the rationale for adding an extra priming dose in individuals from the age of 50 years. Clin Infect Dis. 2019.","DOI":"10.1093\/cid\/ciz176"},{"key":"2025121223231447000_12.4.e061228.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204844","article-title":"Tick-Borne encephalitis: a 43-year summary of epidemiological and clinical data from Latvia (1973 to 2016)","volume":"13","author":"Zavadska","year":"2018","journal-title":"PLoS One"},{"key":"2025121223231447000_12.4.e061228.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-020-01943-w","article-title":"The envelope protein of tick-borne encephalitis virus influences neuron entry, pathogenicity, and vaccine protection","volume":"17","author":"Lindqvist","year":"2020","journal-title":"J Neuroinflammation"},{"key":"2025121223231447000_12.4.e061228.20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/joim.12625","article-title":"Tick-Borne encephalitis in patients vaccinated against this disease","volume":"282","author":"Lotri\u010d-Furlan","year":"2017","journal-title":"J Intern Med"},{"key":"2025121223231447000_12.4.e061228.21","doi-asserted-by":"crossref","unstructured":"Schmidt AJ , Altpeter E , Graf S . Tick-Borne encephalitis (TBE) in Switzerland: does the prolongation of vaccine booster intervals result in an increased risk of breakthroughs? J Travel Med 2021.","DOI":"10.1093\/jtm\/taab158"},{"key":"2025121223231447000_12.4.e061228.22","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2014.19.13.20756","article-title":"Epidemiology of tick-borne encephalitis in Switzerland, 2005 to 2011","volume":"19","author":"Schuler","year":"2014","journal-title":"Euro Surveill"},{"key":"2025121223231447000_12.4.e061228.23","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/14760584.2017.1358620","article-title":"Systematic literature review comparing rapid 3-dose administration of the GSK tick-borne encephalitis vaccine with other primary immunization schedules","volume":"16","author":"Galgani","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"2025121223231447000_12.4.e061228.24","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101876","article-title":"Immunogenicity and safety of the tick-borne encephalitis vaccination (2009-2019): a systematic review","volume":"37","author":"Rampa","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"2025121223231447000_12.4.e061228.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ttbdis.2021.101779","article-title":"Can the booster interval for the tick-borne encephalitis (TBE) vaccine 'FSME-IMMUN' be prolonged? - A systematic review","volume":"12","author":"Steffen","year":"2021","journal-title":"Ticks Tick Borne Dis"},{"key":"2025121223231447000_12.4.e061228.26","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0264-410X(98)00272-2","article-title":"Vaccination against tick-borne encephalitis under therapeutic immunosuppression. reduced efficacy in heart transplant recipients","volume":"17","author":"Dengler","year":"1999","journal-title":"Vaccine"},{"key":"2025121223231447000_12.4.e061228.27","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.vaccine.2015.12.029","article-title":"Tick-Borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study","volume":"34","author":"Hertzell","year":"2016","journal-title":"Vaccine"},{"key":"2025121223231447000_12.4.e061228.28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s15010-002-2020-6","article-title":"Immunological response in HIV-positive patients vaccinated against tick-borne encephalitis","volume":"31","author":"Panasiuk","year":"2003","journal-title":"Infection"},{"key":"2025121223231447000_12.4.e061228.29","doi-asserted-by":"crossref","unstructured":"Jilich D , Maly M , Kosina P , et al . Immunogenicity and safety of rapid scheme vaccination against tick-borne encephalitis in HIV-1 infected persons. Epidemiol Infect. 2021;:e41.;149.","DOI":"10.1017\/S0950268821000194"},{"key":"2025121223231447000_12.4.e061228.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.09.069"},{"key":"2025121223231447000_12.4.e061228.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.02.001"},{"key":"2025121223231447000_12.4.e061228.32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.vaccine.2021.12.028","article-title":"Effectiveness of TBE vaccination in southern Germany and Latvia","volume":"40","author":"Erber","year":"2022","journal-title":"Vaccine"},{"key":"2025121223231447000_12.4.e061228.33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3390\/vaccines9080932","article-title":"TBE vaccination breakthrough Cases-Does age matter?","volume":"9","author":"Schmitt","year":"2021","journal-title":"Vaccines"},{"key":"2025121223231447000_12.4.e061228.34","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.vaccine.2004.07.002","article-title":"Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation","volume":"23","author":"Rendi-Wagner","year":"2004","journal-title":"Vaccine"},{"key":"2025121223231447000_12.4.e061228.35","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tav020"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-061228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:23:24Z","timestamp":1765610604000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-061228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,22]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1136\/bmjopen-2022-061228"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-061228","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}